Lyell Immunopharma, Inc. (LYEL)
NASDAQ:LYEL
Want to see LYEL full AI Analyst Report?
LYEL Stock Chart & Stats
$24.01
-$0.01(-1.66%)
At close: 4:00 PM EST
$24.01
-$0.01(-1.66%)
Day’s Range― - ―
52-Week Range$8.46 - $45.00
Previous CloseN/A
Volume124.06K
Average Volume (3M)74.95K
Market Cap
$320.14M
Enterprise Value$353.10M
Total Cash (Recent Filing)$254.02M
Total Debt (Recent Filing)$39.49M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 12, 2026EPS Estimate
-2.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.98
Shares Outstanding23,334,087
10 Day Avg. Volume75,611
30 Day Avg. Volume74,954
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.12
Price to Sales (P/S)14614.51
P/FCF Ratio-3.49
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue11.39K
Enterprise Value/Gross Profit-153.45
Enterprise Value/Ebitda-1.48
Forecast
1Y Price Target
$37.50Price Target Upside56.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-7.53
Revenue Forecast (FY)$11.71K
Bulls Say, Bears Say
Bulls Say
Balance Sheet FlexibilityReported low debt relative to equity (debt-to-equity ~0.14) gives Lyell structural balance-sheet flexibility versus many early-stage peers. This reduces near-term refinancing pressure, preserves optionality to fund clinical programs or form partnerships, and supports multimonth operational continuity.
Focused Therapeutic PlatformLyell’s platform targets T-cell dysfunction and exhaustion with engineered T-cell approaches (CAR T and TIL) focused on solid tumors. That scientific focus addresses a durable unmet need, supports multiple program extensions, and creates a repeatable product and partnership pathway over months to years.
Transparent Cash Loss DynamicsFCF closely tracking net loss indicates reported losses largely reflect real cash usage rather than hidden noncash distortions. This alignment improves predictability of cash burn and aids runway forecasting, making financing needs easier to model for durable planning over several quarters.
Bears Say
High Cash BurnSustained, large negative operating and free cash flow implies ongoing, material funding requirements. Over the coming months this structurally increases dilution risk, limits strategic flexibility, and forces dependence on external financing or partnerships to continue clinical development and program advancement.
Minimal And Declining RevenueNegligible and falling revenue highlights scant non-dilutive income from collaborations or commercial activity. Structurally, this weak revenue base cannot offset cash burn, increasing reliance on capital markets and reducing financial resilience across the next several quarters.
Eroding Equity From Cumulative LossesMaterial reduction in shareholders' equity over time reflects cumulative losses and capital changes, shrinking the balance-sheet buffer. This erosion amplifies financing constraints, raises dilution risk, and limits the company’s ability to absorb setbacks or pursue multiple large trials concurrently.
Lyell Immunopharma News
LYEL FAQ
What was Lyell Immunopharma, Inc.’s price range in the past 12 months?
Lyell Immunopharma, Inc. lowest stock price was $8.46 and its highest was $45.00 in the past 12 months.
What is Lyell Immunopharma, Inc.’s market cap?
Lyell Immunopharma, Inc.’s market cap is $320.14M.
When is Lyell Immunopharma, Inc.’s upcoming earnings report date?
Lyell Immunopharma, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 60 days.
How were Lyell Immunopharma, Inc.’s earnings last quarter?
Lyell Immunopharma, Inc. released its earnings results on May 06, 2026. The company reported -$1.1 earnings per share for the quarter, beating the consensus estimate of -$1.312 by $0.212.
Is Lyell Immunopharma, Inc. overvalued?
According to Wall Street analysts Lyell Immunopharma, Inc.’s price is currently Undervalued.
Does Lyell Immunopharma, Inc. pay dividends?
Lyell Immunopharma, Inc. does not currently pay dividends.
What is Lyell Immunopharma, Inc.’s EPS estimate?
Lyell Immunopharma, Inc.’s EPS estimate is -2.03.
How many shares outstanding does Lyell Immunopharma, Inc. have?
Lyell Immunopharma, Inc. has 23,334,087 shares outstanding.
What happened to Lyell Immunopharma, Inc.’s price movement after its last earnings report?
Lyell Immunopharma, Inc. reported an EPS of -$1.1 in its last earnings report, beating expectations of -$1.312. Following the earnings report the stock price went down -3.789%.
Which hedge fund is a major shareholder of Lyell Immunopharma, Inc.?
Currently, no hedge funds are holding shares in LYEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lyell Immunopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.50 (56.18% Upside)
$37.50 (56.18% Upside)
Blogger Sentiment
Bullish
LYEL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 98.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
106.67%
12-Months-Change
Fundamentals
Return on Equity
-85.71%
Trailing 12-Months
Asset Growth
-18.42%
Trailing 12-Months
Company Description
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. (LYEL) is a firm specializing in T cell reprogramming, dedicated to crafting T cell therapies for individuals battling solid tumors. The company's therapeutic innovation relies on advanced technology platforms: Gen-R, an ex vivo genetic reprogramming technique engineered to counteract T cell exhaustion, and Epi-R, an ex vivo epigenetic reprogramming method designed to cultivate T cells with sustained stem-like properties. Its development pipeline features notable candidates such as LYL797, a T cell product aimed at non-small cell lung cancer and triple-negative breast cancers; LYL845, intended for a broad range of solid tumors; and NY-ESO-1, focusing on synovial sarcoma and other specific solid tumor conditions. Additionally, Lyell holds a research and development collaboration and licensing agreement with GlaxoSmithKline for the NY-ESO-1 initiative. Founded in 2018, the company's main office is situated in South San Francisco, California.
LYEL Stock 12 Month Forecast
Average Price Target
$37.50
▲(56.18% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
Mereo Biopharma Group Plc
―
Replimune Group
―
―
Ownership Overview
28.56% Insiders
7.22% Mutual Funds
36.69% Other Institutional Investors
23.47% Public Companies and
Individual Investors